[Biotherapies to treat necrotizing vasculitis].

作者信息

Guillevin L

机构信息

Inserm U 1060, service de médecine interne, hôpital Cochin, université Paris Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.

出版信息

Rev Med Interne. 2010 Dec;31 Suppl 3:S304-6. doi: 10.1016/j.revmed.2010.10.001. Epub 2010 Nov 4.

DOI:10.1016/j.revmed.2010.10.001

PMID:21055849

Abstract

摘要

相似文献

[Biotherapies to treat necrotizing vasculitis].

Rev Med Interne. 2010 Dec;31 Suppl 3:S304-6. doi: 10.1016/j.revmed.2010.10.001. Epub 2010 Nov 4.

Therapeutic strategies for systemic necrotizing vasculitides.

Allergol Int. 2007 Jun;56(2):105-11. doi: 10.2332/allergolint.R-07-144. Epub 2007 May 1.

Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides.

Isr Med Assoc J. 2008 Jan;10(1):89-91.

[Off-label use of biological therapies in systemic diseases].

Rev Med Interne. 2010 Dec;31 Suppl 3:S307-14. doi: 10.1016/j.revmed.2010.09.015. Epub 2010 Oct 30.

[Twenty-seven years' activities of the French vasculitis study group (FVSG)].

Rev Med Interne. 2007 Dec;28 Suppl 4:S263-5. doi: 10.1016/j.revmed.2007.09.002. Epub 2007 Oct 5.

Biological therapies: new treatment options for ANCA-associated vasculitis?

Expert Opin Biol Ther. 2007 Apr;7(4):521-33. doi: 10.1517/14712598.7.4.521.

Advances in the use of biologic agents for the treatment of systemic vasculitis.

Curr Opin Rheumatol. 2009 Jan;21(1):3-9. doi: 10.1097/BOR.0b013e32831d28b3.

Immunotherapies in dermatologic disorders.

Med Clin North Am. 2012 May;96(3):565-82, x-xi. doi: 10.1016/j.mcna.2012.04.004. Epub 2012 May 22.

Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.

Cutis. 2003 Jan;71(1):25-9.

Pulmonary affectation of vasculitis.

Arch Bronconeumol. 2012 Nov;48(11):410-8. doi: 10.1016/j.arbres.2012.04.007. Epub 2012 Jun 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Biotherapies to treat necrotizing vasculitis].

Rev Med Interne. 2010 Dec;31 Suppl 3:S304-6. doi: 10.1016/j.revmed.2010.10.001. Epub 2010 Nov 4.

Therapeutic strategies for systemic necrotizing vasculitides.

Allergol Int. 2007 Jun;56(2):105-11. doi: 10.2332/allergolint.R-07-144. Epub 2007 May 1.

Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides.

Isr Med Assoc J. 2008 Jan;10(1):89-91.

[Off-label use of biological therapies in systemic diseases].

Rev Med Interne. 2010 Dec;31 Suppl 3:S307-14. doi: 10.1016/j.revmed.2010.09.015. Epub 2010 Oct 30.

[Twenty-seven years' activities of the French vasculitis study group (FVSG)].

Rev Med Interne. 2007 Dec;28 Suppl 4:S263-5. doi: 10.1016/j.revmed.2007.09.002. Epub 2007 Oct 5.

Biological therapies: new treatment options for ANCA-associated vasculitis?

Expert Opin Biol Ther. 2007 Apr;7(4):521-33. doi: 10.1517/14712598.7.4.521.

Advances in the use of biologic agents for the treatment of systemic vasculitis.

Curr Opin Rheumatol. 2009 Jan;21(1):3-9. doi: 10.1097/BOR.0b013e32831d28b3.

Immunotherapies in dermatologic disorders.

Med Clin North Am. 2012 May;96(3):565-82, x-xi. doi: 10.1016/j.mcna.2012.04.004. Epub 2012 May 22.

Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.

Cutis. 2003 Jan;71(1):25-9.

Pulmonary affectation of vasculitis.

Arch Bronconeumol. 2012 Nov;48(11):410-8. doi: 10.1016/j.arbres.2012.04.007. Epub 2012 Jun 6.